The introduction of a 750mcg teriparatide injection in Australia has been relatively limited , with distribution primarily via specialist clinicians and designated treatment centers. Initial sales figures for this increased strength remain undisclosed from the supplier , although reports suggest controlled adoption rates . Patient access is managed